In the Claims:

Please cancel claim 23 and amend claims 30-37 as follows.

C6 30. (Amended)A homogeneous, solid, water-soluble product consisting of at least one active substance selected from the group consisting of low aqueous solubility ($<1.10^{-4}$ M/Lit, $<1.10^{-6}$M/Lit) of the group amphotericin B, an adriamyciine analogue, apazone, azathioprine, bromazepam, camptothecin, clonazepam, cyclosporine A, diazepam, dicumaroo, digitoxine, dipyrimdamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconzaole, miconazole, niflumic acid, oxazepam, phenobarbital, phenytoin, progresterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid and warfarin; and also consisting of at least one protein selected from the group consisting of human serum albumin, immunoglobulin, glycoprotein, interferon and interleukin and some other natural or recombinant human plasma fraction
where the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds and wherein the molar ratio of the said active substance and the said protein fraction is within the range of 1:0.05 to 1:100.

31. (Amended)A homogenous, solid, water-soluble product according to claim 30 consisting of a taxonoide of the general formula I - in the formula
R^1 represents tert. butyl-oxy-carboxylic acid amide or benzoyl amide,
R^2 represents hydrogen or any acyl group and of a plasma protein fraction.

32. (Amended)A homogenous, solid, water-soluble product according to claim 30, wherein the active substance is paclitaxel and the protein is selected from the group consisting of human

C6 serum albumin, recombinant human plasma albumin and γ-globulin.

33. (Amended)A homogeneous, solid, water-soluble product according to claim 30, wherein the active substance is amphotericin B and the protein is selected from the group consisting of human serum albumin, recombinant human plasma albumin and γ-globulin.

34. (Amended)A homogenous, solid, water-soluble product according to claim 30, wherein the active substance is camptothecin and the protein is selected from the group consisting of human serum albumin, recombinant human plasma albumin and γ-globulin.

35. (Amended)A homogenous, solid, water-soluble product according to claim 30, wherein the active substance is carbamazepin and the protein is selected from the group consisting of human serum albumin, recombinant human plasma albumin and γ-globulin.

36. (Amended)A homogenous, solid, water-soluble product according to claim 30, wherein the active substance is cyclosporin A and the protein is selected from the group consisting of human serum albumin, recombinant human plasma albumin and γ-globulin.

37. (Amended)A homogenous, solid, water-soluble product according to claim 30, wherein the active substance is propofol and the protein is selected from the group consisting of human

C6 Concluded

serum albumin, recombinant human plasma albumin and γ-globulin.

Please add the following new claims:

C7

93. (New) A homogeneous, solid, water-soluble product according to claim 30, wherein the active substance and the protein fraction are bound to each other by way of non-covalent bonds and wherein the molar ratio of the active substance and the protein fraction is within the range of 1:0.1 to 1:50.

94. (New) A homogenous, solid, water-soluble product according to claim 31, wherein the acyl group of R^2 is an acetyl group.

add E1

REMARKS

Reconsideration and withdrawal of the objections to and rejections of this application are respectfully requested in view of this amendment and the following remarks.

In response to the Examiner's objection in the August 23, 2001 Office Action, Applicants respectfully submit a section titled "Brief Description of the Figures" describing the figures. The section is now included after the section titled "Brief Summary of the Invention". There is no new matter as the description is present in the originally filed application. Applicants believes that the newly submitted section should satisfy the requirement under 37 C.F.R. 1.74.